Plerixafor-Tacrolimus Regimen for Low-Side-Effect Allograft Acceptance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunosuppressive therapies for organ transplantation, such as those using calcineurin inhibitors, are associated with significant side effects and complications, and there is a need for treatments that can induce clinical tolerance and minimize long-term immunosuppression.
Innovation Solution
The administration of a stem cell mobilizer, AMD3100, in combination with an immunosuppressive agent, Tacrolimus, to promote the mobilization of recipient stem cells, which can repopulate and regenerate rejecting allografts, allowing for minimal immunosuppression and rapid weaning.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If calcineurin inhibitors are used for immunosuppression in organ transplantation, then graft function is maintained, but side effects such as infections, diabetes, hypertension, nephrotoxicity and malignancy occur
Solution Approach 1:
The invention changes the pharmacological parameters by using low-dose tacrolimus (0.03-0.1 mg/kg/day) combined with plerixafor mobilization, rather than conventional high-dose immunosuppression. This parameter change maintains graft function while reducing immunosuppression-related side effects
Solution Approach 2:
The invention introduces plerixafor as an intermediary agent that mobilizes stem cells to the graft site. These mobilized stem cells serve as mediators that promote graft acceptance and reduce the need for high-dose immunosuppression, thereby reducing side effects
2Duration of action of stationary object
If conventional immunosuppression is used to prevent rejection, then graft survival is improved, but quality of life and survival rates are reduced due to chronic immunosuppression side effects
Solution Approach 1:
The invention performs preliminary action by mobilizing stem cells to the graft site before rejection occurs. This preemptive stem cell mobilization creates a protective environment that reduces the need for long-term high-dose immunosuppression, thereby improving quality of life while maintaining graft survival
Solution Approach 2:
The invention changes the immunosuppression dosage parameter from conventional high doses to low doses (0.03-0.1 mg/kg/day tacrolimus), combined with periodic plerixafor administration. This parameter change maintains adequate graft protection while significantly reducing chronic side effects
3Quantity of substance
If stem cell mobilization is used to promote graft acceptance, then immunosuppression can be reduced, but additional therapeutic agents are required
Solution Approach 1:
The invention merges two therapeutic approaches: stem cell mobilization with plerixafor and immunosuppression with tacrolimus. This combination allows for reduced immunosuppression doses while maintaining graft acceptance, with the added benefit that plerixafor is administered intermittently rather than continuously
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to the field of organ transplantation. In one aspect, the present invention provides methods of treating an organ transplant recipient comprising administering to the recipient a therapeutically effective amount of a stem cell mobilizer and an immunosuppressive agent. In particular embodiments, the present invention provides a method of treating an organ transplant recipient comprising administering to the recipient a therapeutically effective amount of an agent that mobilizes CD34+ and/or CD133+ stem cells and a low dose of an immunosuppressive agent.